Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalasse… Read more
Fulcrum Therapeutics Inc (FULC) - Total Liabilities
Latest total liabilities as of September 2025: $16.49 Million USD
Based on the latest financial reports, Fulcrum Therapeutics Inc (FULC) has total liabilities worth $16.49 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Fulcrum Therapeutics Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Fulcrum Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Fulcrum Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Fulcrum Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nanjing Julong Science & Technology Co Ltd Class A
SHE:300644
|
China | CN¥1.50 Billion |
|
Polaris Group
TW:6550
|
Taiwan | NT$3.99 Billion |
|
Netlist Inc
OTCQB:NLST
|
USA | $69.64 Million |
|
Bank of Kaohsiung Ltd
TW:2836
|
Taiwan | NT$333.40 Billion |
|
Hangzhou Shenhao Technology Co Ltd
SHE:300853
|
China | CN¥1.00 Billion |
|
Taiwan Fire & Marine Insurance Co Ltd
TW:2832
|
Taiwan | NT$11.49 Billion |
|
Lingda Group Co Ltd
SHE:300125
|
China | CN¥1.58 Billion |
|
Sharda Cropchem Limited
NSE:SHARDACROP
|
India | ₹22.27 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Fulcrum Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Fulcrum Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Fulcrum Therapeutics Inc (2017–2024)
The table below shows the annual total liabilities of Fulcrum Therapeutics Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $17.68 Million | -21.41% |
| 2023-12-31 | $22.50 Million | -18.89% |
| 2022-12-31 | $27.74 Million | +18.25% |
| 2021-12-31 | $23.46 Million | -31.79% |
| 2020-12-31 | $34.40 Million | +47.71% |
| 2019-12-31 | $23.29 Million | +138.32% |
| 2018-12-31 | $9.77 Million | +223.76% |
| 2017-12-31 | $3.02 Million | -- |